From the Faculty of Pharmaceutical Sciences, Toyama
Medical and Pharmaceutical University, Toyama 930-0194, Japan, the
§ Bio-oriented Technology Research Advancement Institution,
Saitama 331-8537, Japan, the ¶ Division of Biological Sciences,
Graduate School of Science, Hokkaido University, Sapporo 060-0810, Japan, and the
Institute of Low Temperature Science, Hokkaido
University, Sapporo 060-0819, Japan
Received for publication, November 4, 2002, and in revised form, December 26, 2002
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth-blocking peptide (GBP) is a small (25 amino acids) insect cytokine with a variety of functions: controlling
the larval development of lepidopteran insects, acting as a mitogen for
various types of cultured cells, and stimulating insect blood cells.
The aromatic residues of GBP (Phe-3, Tyr-11, and Phe-23) are highly conserved in the ENF peptide family found in lepidopteran insects. We
investigated the relationship between the biological activities and
structural properties of a series of GBP mutants, in which each of the
three aromatic residues is replaced by a different residue. The results
of the hemocytes-stimulating assays of GBP mutants indicated that Phe-3
is the key residue in this activity: Ala or Tyr replacement resulted in
significant loss of the activity, but Leu replacement did not. The
replacements of other aromatic residues hardly affected the activity.
On the other hand, NMR analysis of the mutants suggested that Tyr-11 is
a key residue for maintaining the core structure of GBP. Surprisingly,
the Y11A mutant maintained its biological activity, although its
native-like secondary structure was disordered. Detailed analyses of
the 15N-labeled Y11A mutant by heteronuclear NMR
spectroscopy showed that the native-like Growth-blocking peptide
(GBP)1 was first identified
as a growth factor that retards the larval development of the armyworm, Pseudaletia separata, parasitized by the parasitoid wasp,
Cotesia kariyai (1, 2). Injection of GBP into
non-parasitized armyworm larvae during the last larval instar
retards larval growth and causes a delay in pupation (3, 4). Recently,
GBP has been shown to demonstrate multifunctionality: cell
proliferation, stimulation of immune cells (plasmatocytes), and
paralysis (5). GBP homologous peptides have been identified from other
lepidopteran species and, based on their consensus
N-terminal sequences (Glu-Asn-Phe), have been expediently
designated the ENF peptide family (Fig. 1) (6). Although each of these peptide
family members was originally identified as a unique biological active
peptide (1, 8, 11, 12), it has since been demonstrated that some of
them exert multiple activities, such as larval retardation,
plasmatocyte stimulation, and paralysis (6, 13, 14). Therefore, it
seems reasonable to categorize the ENF family peptides as a cytokine family primarily found in insects.
-sheet structure of Y11A
was induced by the addition of 2,2,2-trifluoroethanol. The
results suggest that Y11A has a tendency to form a native-like
structure, and this property may give the Y11A mutant native-like activity.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (63K):
[in a new window]
Fig. 1.
Sequence alignment of GBP and other ENF
peptides. GBP from P. separata (P.s. GBP),
GBP from Mamestra brassicae (M.b. GBP),
Spodoptera litura (S.l. GBP) (5), paralitic
peptides from Trichoplusia ni (T.n. PP (paralytic
peptide) I, II) (7), Heliothis
virescens (H.v. PP I, II), Manduca
sexta (M.s. PP I, II), Spodoptera
exigua (S.e. PP I-III) (8), Antheraea
yamamai (A.y. PP) (9), Bombyx mori
(B.m. PP) (10), plasmatocyte-spreading peptide from
Pseudopulusia includens (P.i. PSP (plasmatocyte
spreading peptide)) (11) and cardioactive peptide from Spodoptera
eridania (s.e. CAP (cardioactive peptide)) (12) were
aligned. Residues within the boxes are identical between the
peptides. Phe-3, Tyr-11, and Phe-23 are shaded in
gray.
GBP exhibits a strong mitogenic activity on cultured cells, such as
insect Sf9 and human keratinocytes. Interestingly, GBP and
epidermal growth factor (EGF) are more or less equivalent with respect
to their cell proliferation activity in keratinocytes cells (5). Recent
studies have indicated that GBP binds directly to EGF receptors in
keratinocytes and phosphorylates their tyrosine residues as EGF upon
stimulating mitogenesis of keratinocyte cells (15). Structural analyses
of GBP as well as other ENF peptides using NMR spectroscopy have
revealed that they consist of a core region with a striking similarity
to the C-terminal -loop domain of EGF and short disordered N and C
termini (16-18). A previous study demonstrated that the minimal
structure of GBP-maintaining mitogenic activity is 2-23 GBP, whereas
that with plasmatocyte-stimulating activity is 1-22 GBP (16). Further,
the GBP mutants, having a Glu, Leu, or Asn residue at Asp-16, lost
their mitogenic activity but retained about 50% of their
plasmatocyte-stimulating activity. Based on these results, we conclude
that specific residues in the structured and unstructured domains of
GBP differently affect the biological activities of GBP.
The present studies focused on the three aromatic amino
acid residues (Phe-3, Tyr-11, and Phe-23) in the GBP molecule (Fig. 2A) because these residues are
highly conserved among the ENF family peptides. We constructed eight
kinds of point-mutated GBP variants at the aromatic residues and
analyzed the relationship between their biological activities and
structures.
|
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Preparation and Identification of Site-direct Mutants of GBP-- The series of GBP mutants prepared by the bacterial expression system are listed in Fig. 2B. The construction of the expression system and purification of GBP were performed according to our procedure.2 cDNA encoding the entire GBP sequence was used as a template, and polymerase chain reactions were performed with each of the mutated GBP primers described previously (19). GBP and site-direct mutants of GBP were expressed as thioredoxin fusion proteins and purified with nickel-nitrilotriacetic acid-agarose (Qiagen). The purified proteins were cleaved by enterokinase enzyme (Invitrogen) and further purified by reverse phase high performance liquid chromatography (HPLC). The wild-type and mutant GBP peptides were judged to be homogeneous after a second analysis by HPLC. The purified GBPs were further confirmed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (Voyager-DE PRO; Applied Biosystems) and N-terminal amino acid sequence analysis (PPSQ-21; Shimadzu). We obtained purified GBP mutants at a rate of about 10 mg per 1 liter of LB medium solution, except in the case of Y11L. In the case of the Y11L mutant, although the thioredoxin fusion Y11L GBP was expressed normally, no fractions that were considered to contain the appropriate Y11L GBP molecule were detected by HPLC analysis after digestion by enterokinase. Compared with the results of HPLC for wild-type GBP or other GBP mutants, an intense fragmentation of peptide was observed. Further N-terminal sequence and mass spectrum analyses revealed that these fragments were decomposed Y11L GBP. Thus, we could not obtain the Y11L mutant.
Plasmatocyte-stimulating Assay-- GBP has a hemocyte-stimulating activity that induces plasmatocytes (a class of insect immune blood cells) to spread on foreign surfaces (6, 11). Plasmatocyte-spreading activities were assayed according to the following procedure, which was slightly modified from that of Clark et al. (11). Hemocytes were collected from full-grown (Day 5) last instar larvae of the armyworm, and plasmatocytes were isolated on Percoll gradients; plasmatocytes were collected from an ~50% Percoll interface. The cells were rinsed twice in Excell-400 medium (JRH Scientific) and resuspended in 100 µl of the same medium containing 100 nM GBP or its analogs. The percentage of plasmatocytes spread in an assay was scored 20 min after mixing cells and peptide by counting 200 cells from a randomly selected view.
NMR Spectroscopy-- Each mutated GBP was dissolved at a final concentration of 1.5-3.0 mM in 350-500 µl of buffer containing 90% H2O/10% D2O, 50% H2O/50% 2,2,2-trifluoroethanol (TFE)-D3, and 100% D2O with 20 mM sodium phosphate at pH 6.5. The NMR experiments were performed on a Bruker DMX-500 spectrometer. The NMR spectra were recorded at 30 °C, and the chemical shifts were measured from the internal standard of sodium 2,2-dimethyl-2-silapentane-5-sulfonate. Double quantum filtered correlation spectroscopy (DQF-COSY) spectra (20), total correlation spectroscopy (TOCSY) spectra (21), and nuclear Overhauser effect spectroscopy (NOESY) spectra with a mixing time of 100-300 ms (22) were recorded during suppression of the water signal by WATER-GATE pulse (23). The NMR spectra of 15N-labeled samples were recorded under the same condition with non-labeled samples using {15N-1H} heteronuclear single quantum coherence (HSQC) (24), 15N-edited TOCSY (25), and 15N-edited NOESY (25).
Cell Growth Assay-- The cell growth assay was performed according to the previously described method (14). Insect High FiveTM cells (Invitrogen) were maintained in modified Grace's medium (MGM; Grace's medium containing 0.33% tissue culture lactoalbumin hydrolysate and 0.33% tissue culture yeastolate (DIFCO)) with 10% fetal bovine serum. After culturing the cells in MGM without fetal bovine serum or any growth factor for 2 days, the cells were cultured in medium containing GBP or an analog plus 1 µCi of [3H]thymidine for 32 h. Cells were washed three times with 0.15 M NaCl, lysed with 100 µl of 0.3 N NaOH, and then the incorporated thymidine was counted using a liquid scintillation counter (LSC-5100; Aloka). Cells were in their exponential growth phase at the time of labeling.
Experimental Injection of GBP and GBP Analogue into
Larva--
The experimental injection method was a modification of the
previously published method of Hayakawa and Ohnishi (5). Day 0 last instar larvae (0.17-0.18 g) of armyworm were injected with the
indicated amounts of GBP and its analog early in the last larval instar
and weighed at 16 h after injection.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Plasmatocyte-stimulating Activity of GBP Mutants--
The assay
for the plasmatocyte-stimulating activity of the GBP mutants indicated
that GBP mutants of Phe-23 (F23A, F23L, and F23Y) and of Tyr-11 (Y11A
and Y11F) showed the highest rates of plasmatocyte stimulation; for
both mutants, the rates of stimulation were almost equivalent to that
of the wild-type GBP (Fig. 3). The
mutation at Phe-3 had a significant effect on this activity: F3A and
F3Y lost the activity, but F3L did not. These results clearly indicated
that Phe-3 is an essential residue for GBP to exert the
plasmatocyte-stimulating activity.
|
NMR Spectra of GBP Mutants--
The chemical shift assignments of
the GBP mutants were performed using their NOESY and TOCSY spectra to
compare the structural characters between native GBP and its mutants.
DQF-COSY spectra of most GBP mutants are almost similar to the spectrum
of wild-type GBP. However, Y11A showed a completely different DQF-COSY
spectrum in the fingerprint regions (Fig.
4A). 15N-labeled
Y11A was prepared, and its 15N-edited spectra were analyzed
to assign its NMR signals completely (Fig. 4B).
|
Chemical Shift Deviations of GBP Mutants--
The chemical shifts
of CH protons are very sensitive to backbone
conformation and secondary structure (26). The chemical shift
deviations of C
H in amino acid residues of native GBP
and GBP mutants are shown in Fig. 5. A
positive value of chemical shift deviation suggests a
-sheet
structure, and a negative value of chemical shift deviation suggests an
-helix structure (26). The patterns of chemical shift deviation in
GBP mutants resemble that of native GBP, with the exception of the
deviation for Y11A. In particular, the chemical shift deviations of the
-sheet region in wild-type GBP (Tyr-11-Arg-13, Cys-19-Pro-21) also
showed positive values in these mutants. In contrast, Y11A showed a
different chemical shift deviation pattern around the
-sheet region.
The chemical shift deviations of the
-sheet region of Y11A are
smaller than that of native GBP. These results showed that the
native-like
-sheet structure is disordered in Y11A mutants.
|
Biological Activities of Y11A--
To further clarify the
character of Y11A, we investigated two of its other biological
activities, i.e. its mitogenic and larval growth activities.
Y11A showed a strong mitogenic activity, almost equivalent to that of
the wild-type GBP, for insect High Five cells (Fig.
6A). The growth-inhibitory
effect of Y11A on P. separata larvae was also examined (Fig.
6B). Larvae injected with over 4 pmol of GBP gained
significantly less weight than bovine serum albumin-injected larvae.
Y11A was effective when over 40 pmol were injected to larvae.
Therefore, the growth-inhibitory activity of Y11A on larvae was less
effective than that of native GBP, but the Y11A mutant did retain some
degree of this activity.
|
NMR Analysis of Y11A in TFE Solvent--
The Y11A mutant
maintained almost the same activities as the wild type, although the
secondary structure was disordered. These results raised the
possibility that Y11A GBP might have a tendency to form the native-like
structure easily. To investigate this possibility, we examined the
structural alteration of the Y11A mutant in TFE solvent. TFE has been
shown to induce and stabilize intrinsic secondary structures of the
peptides, such as -helices,
-turns, or
-sheets (27). Chemical
shift deviations of C
H in amino acid residues of native
GBP and Y11A in 50% TFE solvent are shown in Fig.
7. Compared with the pattern of the
chemical shift deviation of Y11A in a water solution (Fig. 5), that of Y11A in 50% TFE solvent more closely resembles the pattern of native
GBP. In particular, the chemical shifts of the residues, which form a
-sheet structure in native GBP (Tyr-11-Arg-13, Cys-19-Pro-21), showed remarkable change and the feature of a
-sheet structure in
Y11A dissolved in TFE solution. These results seem to suggest that Y11A
GBP has the potential to hold the native-like core
-sheet structure.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
GBP mutants at the aromatic residues, Phe-3, Tyr-11, and Phe-23, show significant differences in their biological activities and structural characteristics. Phe-3 is important for the plasmatocyte-stimulating activity because the mutants at Phe-3 (F3A and F3Y) significantly reduced the activity or lost it (Fig. 3). The fact that the activity of F3L was stronger than that of F3Y suggests that the hydrophobicity of the side chain at the position of Phe-3 promotes this activity. In contrast with the plasmatocyte-stimulating activity, Phe-3 does not play an important role in maintaining the structure of GBP since the point mutations at Phe-3 had little effect on the chemical shift deviation patterns of the backbone structure (Fig. 5).
The GBP mutations at Phe-23 did not affect either the plasmatocyte-stimulating activity or the backbone structure. Deletion of Tyr-24 and Gln-25 from the Phe-23 mutants also had no effect on their characters. Prior studies have shown that the deletion mutation of 1-22 GBP resulted in a loss of the mitogenic activity, although the plasmatocyte-stimulating activity was maintained in this mutant (14). From these data, it is reasonable to assume that Phe-23 plays an essential role only in the mitogenic activity.
Recent NMR studies of GBP as well as other ENF peptides have suggested
that the aromatic residue at position 11 is a key residue for
maintenance of the -sheet structure (16-18). Many NOEs have been
observed between the side chain of Tyr-11 and other hydrophobic residues, suggesting the existence of hydrophobic interactions between
them. In the present study, we were unable to prepare the Y11L mutant,
probably due to proteolysis. On the other hand, Y11F has almost the
same NMR spectra and biological activity as the wild-type GBP.
Therefore, it may be possible to replace Tyr-11 with a phenylalanine
residue and thereby maintain the secondary structure of GBP.
Interestingly, the NMR spectra of Y11A are very different from those of
native GBP (Fig. 4), despite the fact that Y11A maintains almost the
full amount of plasmatocyte-stimulating activity. This mutant is quite
attractive as a model of induced fitting because another mutant, D16
(GBP with a
-Asp bond at Asp-16), has been shown to have a
completely unordered structure and to exert no biological activities
(14, 28). It was difficult to assign the signals of the
1H-two-dimensional NMR spectra of Y11A because of the
extreme overlap of the signals (Fig. 4A). However, we were
able to execute a complete assignment by using 15N-labeled
Y11A (Fig. 4B). Complete assignment of Y11A enabled us to
characterize the detailed structural features of this mutant. The
considerably small values of the chemical shift deviations of
C
H around Tyr-11-Arg-13 and Cys-19-Pro-21,
corresponding to the
-sheet region in wild-type GBP, suggested the
disorder of the native-like
-sheet structure in the Y11A mutant
(Fig. 5). Furthermore, NOE data also suggest that the tertiary
structure of Y11A is completely different from that of the native
peptide. A number of NOE signals of Y11A were considerably decreased,
and the unique NOEs for the
-sheet structure, such as the
interstrand NOE between C
H of Arg-13 and HN of Lys-20,
had completely disappeared (Fig. 8A). We thus concluded that
the native
-sheet structure was disordered in the Y11A mutant.
|
Although the tertiary structure of Y11A was disordered, this mutant
retained the plasmatocyte-stimulating, mitogenic, and growth-retardation activities (Figs. 3 and 6). It seems likely that
Y11A easily forms a -sheet structure upon interaction with target
molecules such as GBP receptor proteins. The decrease in the larval
growth inhibitory activity of Y11A could be explained by the
disappearance of its secondary structure since Y11A is thought to be
more susceptible to proteolysis than the wild-type peptide in
vivo. These hypotheses were strongly supported by NMR analyses of
Y11A in TFE solvent (Fig. 7). Based on the pattern of the chemical
shift deviation of Y11A in TFE, it is most likely that Y11A folds the
native-like core
-sheet structure in this solvent. Furthermore, some
unique NOEs that suggest formation of a
-sheet, such as the
interstrand NOE between C
H of Arg-13 and HN of Lys-20,
were clearly observed in the spectra of Y11A in TFE solvent (Fig. 8).
Investigations of the effects of TFE on peptides have demonstrated that
TFE can stabilize secondary structures (27, 29). In those
studies, the peptides had a tendency to fold into a more stabilized,
low-energy level structure by forming hydrogen bonds in TFE solvent.
Thus, the enhancement of the secondary structure of Y11A in TFE implies
the ease of folding of this mutant into the native structure in
receptor binding, and the considerably high activity of this mutant
could be attributed to this induced-fitting model.
In conclusion, we have shown the roles of each aromatic residue in GBP;
in particular, Phe-3 had significant roles for the biological activity,
and Tyr-11 maintained the structural properties of GBP. The interesting
properties of the Y11A mutant, which maintains its activities despite
its loss of the secondary structure, may be useful clues for a further
investigation of the interaction between ENF family peptides and their receptors.
![]() |
FOOTNOTES |
---|
* This study was supported by the Program for the Promotion of Basic Research Activities for Innovative Biosciences (PROBRAIN), Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
** To whom correspondence should be addressed: Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan. Tel.: 81-76-434-5061; Fax: 81-76-434-5061; E-mail: kawano@ms.toyama-mpu.ac.jp.
Published, JBC Papers in Press, December 27, 2002, DOI 10.1074/jbc.M211251200
2 T. Aizawa, Y. Hayakawa, K. Nitta, and K. Kawano, manuscript in preparation.
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: GBP, growth-blocking peptide; EGF, epidermal growth factor; HPLC, high performance liquid chromatography; MGM, modified Grace's medium; DQF-COSY, double quantum filtered correlation spectroscopy; TOCSY, total correlation spectroscopy; NOESY, nuclear Overhauser effect spectroscopy; HSQC, heteronuclear single quantum coherence; NOE, nuclear Overhauser effect; TFE, 2,2,2-trifluoroethanol.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. |
Hayakawa, Y.
(1990)
J. Biol. Chem.
265,
10813-10816 |
2. |
Hayakawa, Y.
(1991)
J. Biol. Chem.
266,
7982-7984 |
3. | Hayakawa, Y., and Yasuhara, Y. (1993) Insect Biochem. Mol. Biol. 23, 225-231[CrossRef] |
4. | Hayakawa, Y. (1995) J. Insect. Physiol. 41, 1-6[CrossRef] |
5. | Hayakawa, Y., and Ohnishi, A. (1998) Biochem. Biophys. Res. Commun. 250, 194-199[CrossRef][Medline] [Order article via Infotrieve] |
6. | Strand, M. R., Hayakawa, Y., and Clark, K. D. (2000) J. Insect Physiol. 46, 817-824[CrossRef][Medline] [Order article via Infotrieve] |
7. | Skinner, W. S., Dennis, P. A., and Quistad, G. B. (1993) Comp. Biochem. Physiol. 104, 133-135[CrossRef] |
8. |
Skinner, W. S.,
Dennis, P. A.,
Li, J. P.,
Sumerfelt, R. M.,
Carney, R. L.,
and Quistad, G. B.
(1991)
J. Biol. Chem.
266,
12873-12877 |
9. | Seino, A., Sato, Y., Yamashita, T., Sato, Y., and Suzuki, K. (1998) J. Seric. Sci. Jpn. 67, 473-478 |
10. | Ha, S.-D., Nagata, S., Suzuki, A., and Kataoka, H. (1999) Peptides 20, 561-568[CrossRef][Medline] [Order article via Infotrieve] |
11. |
Clark, K. D.,
Pech, L. L.,
and Strand, M. R.
(1997)
J. Biol. Chem.
272,
23440-23447 |
12. | Furuya, K., Hackett, M., Cirelli, M. A., Schegg, K. M., Wang, H., Shabanowitz, J., Hunt, D. F., and Schooley, D. A. (1999) Peptides 20, 53-61[CrossRef][Medline] [Order article via Infotrieve] |
13. | Wang, Y., Jiang, H., and Kanost, M. R. (1999) Insect Biochem. Mol. Biol. 29, 1075-1086[CrossRef][Medline] [Order article via Infotrieve] |
14. |
Aizawa, T.,
Hayakawa, Y.,
Ohnishi, A.,
Fujinitani, N.,
Clark, K. D.,
Strand, M. R.,
Miura, K.,
Koganesawa, N.,
Kumaki, Y.,
Demura, M.,
Nitta, K.,
and Kawano, K.
(2001)
J. Biol. Chem.
276,
31813-31818 |
15. |
Ohnishi, A.,
Oda, Y.,
and Hayakawa, Y.
(2001)
J. Biol. Chem.
276,
37974-37979 |
16. |
Aizawa, T.,
Fujinitani, N.,
Hayakawa, Y.,
Ohnishi, A.,
Ohkubo, T.,
Kawano, K.,
Hikichi, K.,
and Nitta, K.
(1999)
J. Biol. Chem.
274,
1887-1890 |
17. |
Volkman, B. J.,
Anderson, M. E.,
Clark, K. D.,
Hayakawa, Y.,
Strand, M. R.,
and Markley, J. L.
(1999)
J. Biol. Chem.
274,
4493-4496 |
18. | Yu, X.-Q., Prakash, O., and Kanost, M. R. (1999) J. Pept. Res. 54, 256-261[Medline] [Order article via Infotrieve] |
19. | Sekiya, T. (1990) Tanpakushitsu Kakusan Koso. 35, 2977-2991[Medline] [Order article via Infotrieve] |
20. | Rance, M., Sørensen, O. W., Bodenhausen, G., Wagner, G., Ernst, R. R., and Wüthrich, K. (1983) Biochem. Biophys. Res. Commun. 117, 479-485[Medline] [Order article via Infotrieve] |
21. | Braunschweiler, L., and Ernst, R. R. (1983) J. Magn. Reson. 53, 521-528 |
22. | Macura, S., Huang, Y., Suter, D., and Ernst, R. R. (1981) J. Magn. Reson. 43, 259-281 |
23. | Piatto, M., Saudek, V., and Skelenar, V. (1992) J. Biomol. NMR 2, 661-665[Medline] [Order article via Infotrieve] |
24. | Palmer, A. G., III, Cavanagh, J., Wright, P. E., and Rance, M. (1991) J. Magn. Reson. 93, 151-170 |
25. | Kay, L. E., Marion, D., and Bax, A. (1989) J. Magn. Reson. 84, 72-84 |
26. | Wishart, D. S., Sykes, B. D., and Richards, F. M. (1992) Biochemistry 31, 1647-1651[Medline] [Order article via Infotrieve] |
27. |
Reiersen, H.,
and Rees, A. R.
(2000)
Protein Eng.
13,
739-743 |
28. | Hayakawa, Y. (1994) J. Biochem. 115, 15-17[Abstract] |
29. | Ramirez-Alvarado, M., Blanco, F. J., and Serrano, L. (1996) Nat. Struct. Biol. 3, 604-612[Medline] [Order article via Infotrieve] |